Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,467,152,142Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry under nu ...

Core Insights - Investors are considering Banco Santander (SAN) and National Australia Bank Ltd. (NABZY) for potential value opportunities in the Banks - Foreign sector [1] Valuation Metrics - Banco Santander has a Zacks Rank of 2 (Buy), indicating a more favorable earnings estimate revision activity compared to National Australia Bank Ltd., which has a Zacks Rank of 3 (Hold) [3] - SAN's forward P/E ratio is 7.72, significantly lower than NABZY's forward P/E of 14.41, suggesting SAN may be undervalued [5] - The PEG ratio for SAN is 0.81, while NABZY's PEG ratio is 7.67, indicating SAN's expected earnings growth is more favorable [5] - SAN's P/B ratio is 0.93, compared to NABZY's P/B of 1.57, further supporting SAN's valuation attractiveness [6] Value Grades - Based on various valuation metrics, SAN holds a Value grade of A, while NABZY has a Value grade of D, indicating SAN is perceived as a better value investment [6][7]

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies. These figures are just a handful of the metrics value investors tend to look at, but they help show that Banco Santander is likely being undervalued right now. Considering this, as well as the strength of its ear ...

Core Perspective - Qfitlia (fitusiran) has been approved by the US FDA as the first antithrombin-lowering therapy for the routine prophylaxis of hemophilia A and B, providing a significant advancement in treatment options for patients with or without inhibitors [1][10]. Company Insights - Sanofi emphasizes its commitment to innovation in the treatment of rare blood disorders, highlighting Qfitlia's potential to transform hemophilia care through effective bleed protection and reduced treatment burden [3]. - The company is launching HemAssist alongside Qfitlia to offer comprehensive patient support services, including insurance assistance and educational resources [9]. Industry Impact - Qfitlia's unique mechanism allows for the treatment of all types of hemophilia, including those with inhibitors, addressing significant unmet medical needs in the market [4]. - The ATLAS clinical development program has shown that Qfitlia can achieve a significant reduction in annualized bleeding rates (ABR) by 71% for patients without inhibitors and 73% for patients with inhibitors compared to traditional on-demand treatments [7][12]. Clinical Data - In the ATLAS studies, Qfitlia demonstrated low bleed rates with as few as six injections per year, with nearly half of patients experiencing one or fewer bleeds during the open-label extension study [7][12]. - The FDA has also approved the Siemens Healthineers' INNOVANCE Antithrombin assay as a companion diagnostic for Qfitlia, allowing for AT level measurement at no cost to patients [8].

Core Viewpoint - The White House's protectionist policies, particularly tariffs, are expected to negatively impact the U.S. economy more than Europe in the short term, leading to slower growth and higher inflation [2][3][11]. Tariffs and Economic Impact - Tariffs are described as a tax on consumers, which will ultimately slow economic growth and increase inflation [2][11]. - The U.S. has imposed a 25% tariff on all car imports effective from April 2, which has prompted retaliatory measures from the European Union [4]. European Economic Resilience - European banks are positioned to lend more and support the economy, with calls for more flexibility in EU regulations to enhance resilience against financial shocks [6]. - The European economy is viewed optimistically, with Germany's significant role in the eurozone expected to provide a boost despite vulnerabilities in the auto sector due to U.S. tariffs [10]. Monetary Policy Considerations - The European Central Bank is anticipated to cut interest rates by 25 basis points in its next meeting, with recent monetary policy becoming less restrictive [11]. - The uncertainty caused by tariffs complicates decision-making for the ECB, affecting the pace and direction of monetary policy adjustments [12][13].

Core Viewpoint - The US FDA has granted fast track designation to Sanofi's mRNA vaccine candidate aimed at preventing chlamydia infection, highlighting its potential to address a significant public health need [1][2]. Group 1: Vaccine Development - The chlamydia vaccine candidate is designed to protect against primary genital tract infection and reinfection by Chlamydia trachomatis, with a phase 1/2 clinical study planned to evaluate its immunogenicity and safety in adults aged 18 to 29 years [2][8]. - The development of this vaccine is part of the Translational Science Hub, a collaboration involving the Queensland Government, Griffith University, and the University of Queensland, connecting researchers in Australia with Sanofi scientists [5]. Group 2: Public Health Impact - Chlamydia is a common bacterial infection with serious long-term health consequences, including infertility and pregnancy complications, affecting 129 million adults globally in 2020, particularly among adolescents and young adults [3][4]. - Over 80% of chlamydia cases are asymptomatic, leading to untreated infections and unintentional transmission, underscoring the urgent need for a vaccine to prevent rising infection rates [4]. Group 3: Company Overview - Sanofi is an innovative global healthcare company focused on improving lives through scientific advancements, providing life-changing treatments and vaccines while emphasizing sustainability and social responsibility [6].

Availability of the Q1 2025 Aide mémoire Paris, France – March 24, 2025. Sanofi announced today that its Q1 2025 Aide mémoire is available on the "Investors" page of the company's website: First quarter 2025 (sanofi.com) As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various non-comparable items and exclusivity losses as well as the foreign currency impact and share count. Sanofi's first quarter ...

Company Insights - Banco Santander (SAN) is currently experiencing solid earnings estimate revisions, indicating a positive outlook from analysts for both short and long-term prospects [3][4]. - Current quarter earnings estimates have increased from 18 cents per share to 19 cents per share, while current year estimates have risen from 83 cents per share to 88 cents per share [4]. Industry Overview - The Finance sector, where Banco Santander operates, holds a Zacks Industry Rank of 44 out of 247 industries, suggesting it is well-positioned compared to other segments [2]. - A rising trend in the Finance industry is likely benefiting multiple securities, indicating a favorable environment for investments [2][5].

Core Viewpoint - Sanofi has agreed to acquire Dren Bio's bispecific myeloid cell engager, DR-0201, which targets deep B-cell depletion, enhancing its immunology pipeline [1][6]. Company Overview - Sanofi is a global healthcare company focused on innovative treatments and vaccines, aiming to improve patient lives through scientific advancements [11]. - Dren Bio is a clinical-stage biopharmaceutical company developing first-in-class antibody therapeutics for cancer and autoimmune diseases [8]. Product Details - DR-0201 is a bispecific antibody that engages myeloid cells to induce deep B-cell depletion, showing promise in treating autoimmune diseases like lupus [2][5]. - The drug is currently undergoing evaluation in two ongoing phase 1 studies, demonstrating robust B-cell depletion in both pre-clinical and clinical settings [5]. Strategic Implications - The acquisition of DR-0201 is part of Sanofi's strategy to strengthen its position in immunology and address significant unmet medical needs in autoimmune diseases [3][4]. - Sanofi's investment includes an upfront payment of $600 million, with potential future payments of $1.3 billion based on development milestones [6][9]. Operational Aspects - Following the acquisition, Dren Bio will continue to operate independently, focusing on its pipeline of antibody therapeutics [7]. - The transaction is expected to close in Q2 2025, pending regulatory approvals [7].

The British unit of Spanish lender Banco Santander on Wednesday said 750 of its staff were at risk of redundancy as it targets 95 branch closures in the U.K.The decision is part of the bank's broader plans to update its presence from June 2025 and will bring Santander UK's network to 349 branches, including 290 that are full-service, 36 operating with reduced hours and 18 that are counter-free and five Work Cafes."Closing a branch is always a very difficult decision and we spend a great deal of time assessi ...